Key Facts

Founded in 2000
$250 million in development dollars
Over 200 employees in 6 countries
More than 170 global treatment centers
21 peer reviewed publications
More than 1,690 patients treated

Mechanism of Action

Tumor Treating Fields, or TTFields, are low intensity alternating electric fields that work within the frequency range of 100-300 kHz. TTFields disrupt cell division through physical interactions with key molecules during mitosis.

Learn more here

Our Pipeline

Since Novocure began its development activities in 2000, the company has progressed research, both in vitro and in vivo, across a range of solid tumor types, all with the hope of introducing the next major modality in cancer care.

Click here for a pipeline snapshot

Delivered by Investis (opens in a new window)